NeuBio is Precision NeuroBiology

NeuBio utilizes revolutionary AI technology to discover biological factors involved in Parkinson’s Disease, Alzheimer’s Disease, and Amyotrophic Lateral Sclerosis. NeuBio has discovered and validated, in-silico, 141 novel mRNA biomarkers with unparalleled precision and reproducibility.

NeuBio’s biomarkers go beyond epidemiology to specific, novel biological pathways in these diseases.

This breakthrough gives rise to an array of new precision diagnostics and therapeutic pathways that will serve all affected by these devastating diseases.

  • NeuBio is developing a Next-Gen Sequencing Assay in a CLIA-Certified laboratory.

    With a “super panel” of biomarkers across these diseases, NeuBio is developing and validating an array of diagnostic algorithms and ushering in a new era of precision diagnostic products in neurodegenerative diseases.

  • Program 1 - Clinical Trial Screening

    There are currently over 1000 active clinical trials for Parkinson’s, Als and Alzheimer’s (combined).

    However, the failure rate in neurology is the highest in all of the medicine at over 95%.

    It is NeuBio’s mission to change this statistic by helping to ensure that the right patients are in the right trials at the right time in the course of their disease.

  • Objective, validated, scalable diagnostics are sorely needed in neurodegenerative diseases.

    Late-or misdiagnosis can prevent patients from therapeutic intervention, and lifestyle modification that could change the course of their disease progression.

    Objective diagnostics can help patients and their families plan for what’s to come, and as new drugs are approved, may provide therapeutic options that could alter the course of their lives.

  • New Druggable Targets

    Twenty-four of NeuBio’s biomarker discoveries have been identified as potential druggable targets. Through industry partnership, NeuBio is investigating candidate validation for targets focused on the underlying causality of Alzheimer’s, Parkinson’s, and ALS.

“NeuBio is charting the biological maps that will tell physicians, pharma, and patients like me where we actually are, and how to get to our destination. They are like Waze for neurology.”

Andrew Creighton

Founder of Vice Media, Board Member of The Michael J. Fox Foundation for Parkinson's Research

We All Know Someone…

“NeuBio’s mission is to bring actionable insights and solutions to the patients and families impacted by some of the biggest healthcare challenges of our time— Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis (ALS).

Neurological disorders have become the number one cause of global disability, continue to grow at an alarming rate, and cause a shocking financial and emotional toll on society. Our team came together through personal connections to these conditions and seeing their devastating effects drives a profound urgency to our work.

Inspired by the strides being made in precision medicine in oncology and the technological advances in AI and data analytic approaches, our thesis was that the technology & data needed to make a huge impact in neurology was at our fingertips; we just needed to grasp it in a new way. As we’ll show you, we are achieving remarkable things.

Neurology is perhaps only matched in complexity by the machinations of the healthcare system and we are humbled by the opportunity to collaborate with mission-aligned leaders across research, drug development, clinical care, and patient advocacy. Our work is anchored in being of service to the constellations of patients and problem-solvers around these disorders and is guided by curiosity, discipline, and innovation. We believe our approach will make sense of the complexity and help people live better lives”

Marley Bankoff

Co-Founder & CEO NeuBio